Literature DB >> 33486629

Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions.

Jiao Li1, Juan-Juan Gao2, Na Li1, Ya-Wen Wang3.   

Abstract

The aim of this study was to describe the distribution of human papillomavirus (HPV) genotypes among cervical cancers and pre-cancers in Shaanxi province of western China. A total of 17,341 women who were screened for cervical cancer from January 2014 to December 2016, using HPV genotyping and ThinPrep cytologic test were included. The prevalence and attribution of HPV genotypes were stratified by cervical lesion and age group. Of the subjects, 26.3% were infected with HPV, 28.0% of whom had multiple infections. The crude HPV prevalence increased from atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions (ASCUS/LSIL, 64.3%) to high-grade squamous intraepithelial lesions (HSIL, 79.8%) and to invasive cervical cancer (ICC, 89.7%, P < 0.001). The three most prevalent genotypes were HPV 16 (8.0%), 58 (4.2%), and 52 (4.0%), and HPV 16, 31 and 33 were positively correlated with increased severity of cervical lesions. Additionally, the divalent vaccine genotypes HPV 16 and 18 accounted for 68.2% of ICC cases. Although 78.5% of ICC and 60.3% of HSIL cases were attributed to 9-valent vaccine genotypes, the other genotypes not covered by any vaccine still resulted in increases in coverage, with 1.5% for ICC, 5.3% for HSIL, and 13.5% for ASCUS/LSIL. HPV prevalence in western China was consistent with other regions of China. Early vaccination with 9-valent HPV vaccine is recommended in this locality for females younger than 26 years with no prior infection, while divalent the vaccine is more appropriate for women between 26 and 45 years, considering the efficacy, safety and cost-effectiveness of vaccines.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33486629     DOI: 10.1007/s00705-021-04960-z

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  29 in total

1.  Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction.

Authors:  Fangjian Guo; Leslie E Cofie; Abbey B Berenson
Journal:  Am J Prev Med       Date:  2018-05-30       Impact factor: 5.043

Review 2.  Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis.

Authors:  H zur Hausen
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

3.  Comparison of Hybribio GenoArray and Roche human papillomavirus (HPV) linear array for HPV genotyping in anal swab samples.

Authors:  Huey Chi Low; Michelle I Silver; Brandon J Brown; Chan Yoon Leng; Magaly M Blas; Patti E Gravitt; Yin Ling Woo
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

4.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

Authors:  Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Oncol       Date:  2010-10-15       Impact factor: 41.316

5.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 6.  Classification of papillomaviruses.

Authors:  Ethel-Michele de Villiers; Claude Fauquet; Thomas R Broker; Hans-Ulrich Bernard; Harald zur Hausen
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616

7.  Prevalence and Genotype Distribution of HPV Infection in China: Analysis of 51,345 HPV Genotyping Results from China's Largest CAP Certified Laboratory.

Authors:  Zhengyu Zeng; Huaitao Yang; Zaibo Li; Xuekui He; Christopher C Griffith; Xiamen Chen; Xiaolei Guo; Baowen Zheng; Shangwei Wu; Chengquan Zhao
Journal:  J Cancer       Date:  2016-05-25       Impact factor: 4.207

8.  Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.

Authors:  Alejandra Castanon; Rebecca Landy; Francesca Pesola; Peter Windridge; Peter Sasieni
Journal:  Lancet Public Health       Date:  2017-12-19

9.  Prevalence and distribution of HPV types in genital warts in Xi'an, China: a prospective study.

Authors:  Cansheng Zhu; Yaofei Wang; Weihua Mao; Hongshan Zhang; Jiaju Ma
Journal:  BMJ Open       Date:  2019-05-14       Impact factor: 2.692

10.  Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.

Authors:  Kimberley Kavanagh; Kevin G Pollock; Kate Cuschieri; Tim Palmer; Ross L Cameron; Cameron Watt; Ramya Bhatia; Catherine Moore; Heather Cubie; Margaret Cruickshank; Chris Robertson
Journal:  Lancet Infect Dis       Date:  2017-09-28       Impact factor: 25.071

View more
  6 in total

1.  Prevalence and genotype distribution of human papillomavirus infection among women aged 30-65 years in Xi'an, China: a population-based study of 14,655 women.

Authors:  Xiaoxiao Han; Guozhong Song; Yufang Li; Zhaoqiang Dong; Xianchun Yan; Suqing Wang; Huizhen Tian; Xiaohong Wu; Chen Li; Yi Huo
Journal:  Hum Vaccin Immunother       Date:  2021-12-10       Impact factor: 3.452

2.  Trends of cancer mortality in Xi'an City, China: 2005-2020.

Authors:  Ning Chen; Xiao-Yu Zhang; Lin-Lin Ma; Guo-Dong Zhao; Yu-Xiang Yan
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-14       Impact factor: 4.322

Review 3.  Cervical Human Papillomavirus Infection (HPV) and High Oncogenic Risk Genotypes among Women Living with HIV in Asia: A Meta-Analysis.

Authors:  Florian Verrier; Sophie Le Coeur; Tristan Delory
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

4.  Human papillomavirus prevalence and genotype distribution landscapes in Shannan City, Tibet Tibetan Autonomous Region, China.

Authors:  Dilu Feng; Sitian Wei; Jun Chen; Zhicheng Yu; Yeshe Lhamo; Hongbo Wang; Xiaowu Zhu
Journal:  Virol J       Date:  2022-03-18       Impact factor: 4.099

5.  Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions.

Authors:  Heyue Li; Linxia Li; Jianming Sun; Shengdong Dong; Hong Li
Journal:  Pak J Med Sci       Date:  2022 Jul-Aug       Impact factor: 2.340

6.  Trichosanthin inhibits cervical cancer by regulating oxidative stress-induced apoptosis.

Authors:  Chenglu Zhu; Cuilan Zhang; Xiaoming Cui; Jing Wu; Zhizhu Cui; Xiaojuan Shen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.